RGS5 Activators
RGS5 activators encompass a diverse array of compounds that can potentially enhance the expression or activity of RGS5 through various molecular mechanisms. Forskolin, for instance, acts as an activator by influencing the cAMP-PKA pathway, modulating factors that may impact RGS5 expression. Similarly, Y-27632, a selective ROCK inhibitor, may activate RGS5 by influencing the RhoA/ROCK pathway, relieving the inhibitory effects on RGS5. Retinoic Acid, a derivative of vitamin A, can potentially activate RGS5 through the retinoic acid signaling pathway. As RGS5 expression is regulated by retinoic acid receptors, Retinoic Acid may act as a direct activator by modulating this pathway. NS1619, a BKCa channel opener, may activate RGS5 by influencing calcium signaling, as RGS5 is involved in calcium-dependent signaling.
Furthermore, Bay 11-7082, a NF-κB inhibitor, may activate RGS5 by suppressing NF-κB-mediated inhibition. Inhibition of NF-κB can relieve the negative regulation imposed on RGS5, potentially leading to increased expression. PD98059, a MEK inhibitor, acts as an activator by influencing the MAPK/ERK pathway, modulating factors involved in RGS5 regulation. Prostaglandin E1 (Alprostadil) can potentially activate RGS5 through the prostaglandin signaling pathway, influencing RGS5 expression. Calcimycin (A23187), a calcium ionophore, may activate RGS5 by inducing intracellular calcium flux, modulating calcium-dependent signaling cascades. TPA, a PKC activator, may activate RGS5 through the PKC signaling pathway, leading to downstream changes in RGS5 expression. SB203580, a p38 MAPK inhibitor, may activate RGS5 by suppressing the inhibitory effects of p38 MAPK on RGS5 expression. Genistein, a tyrosine kinase inhibitor, can potentially activate RGS5 by influencing tyrosine kinase signaling pathways. 8-Bromo-cAMP, a cAMP analog, may activate RGS5 through the cAMP-PKA pathway, mimicking the effects of cAMP.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, an adenylyl cyclase activator, may activate RGS5 through the cAMP-PKA pathway. Forskolin elevates intracellular cAMP levels, leading to the activation of protein kinase A (PKA). Activated PKA can modulate factors that may influence RGS5 expression, making Forskolin a potential indirect activator through the cAMP-PKA signaling cascade. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a selective ROCK (Rho-associated protein kinase) inhibitor, may activate RGS5 by influencing the RhoA/ROCK pathway. Inhibition of ROCK by Y-27632 can affect downstream signaling events, potentially impacting RGS5 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid, a derivative of vitamin A, may activate RGS5 through the retinoic acid signaling pathway. Retinoic Acid influences gene expression by binding to retinoic acid receptors (RARs). As RGS5 expression is regulated by retinoic acid receptors, Retinoic Acid can act as a direct activator by modulating the retinoic acid signaling pathway, potentially leading to increased RGS5 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082, an inhibitor of NF-κB activation, may activate RGS5 by suppressing NF-κB-mediated inhibition. NF-κB has been reported to negatively regulate RGS5 expression. Inhibition of NF-κB by Bay 11-7082 can relieve this suppression, potentially leading to increased RGS5 levels. Consequently, Bay 11-7082 may act as an indirect activator of RGS5 through the modulation of NF-κB signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, may activate RGS5 by influencing the MAPK/ERK pathway. MEK inhibition by PD98059 can dampen the MAPK/ERK signaling cascade, potentially impacting factors involved in RGS5 regulation. As RGS5 expression is linked to the MAPK/ERK pathway, PD98059 may act as an indirect activator by modulating this signaling cascade. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1, also known as Alprostadil, may activate RGS5 through the prostaglandin signaling pathway. Prostaglandin E1 binds to prostaglandin receptors, initiating downstream signaling events. As RGS5 expression can be influenced by prostaglandin signaling, Prostaglandin E1 may act as a direct activator by modulating this pathway, potentially leading to increased RGS5 expression. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcimycin, also known as A23187, a calcium ionophore, may activate RGS5 by inducing intracellular calcium flux. Elevated intracellular calcium levels can influence various signaling pathways, potentially including those related to RGS5 regulation. Calcimycin may act as an indirect activator of RGS5 by modulating calcium-dependent signaling cascades, leading to changes in RGS5 expression or activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a PKC activator, may activate RGS5 through the PKC signaling pathway. Activation of PKC by PMA can lead to phosphorylation events and downstream signaling changes. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, may activate RGS5 by influencing tyrosine kinase signaling pathways. Inhibition of tyrosine kinases by Genistein can affect downstream signaling events, potentially impacting RGS5 expression. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP, a cell-permeable cAMP analog, may activate RGS5 through the cAMP-PKA pathway. By mimicking the effects of cAMP, 8-Bromo-cAMP can activate PKA and downstream signaling events. As RGS5 expression may be influenced by the cAMP-PKA pathway, 8-Bromo-cAMP may act as a potential indirect activator by modulating this signaling cascade, leading to increased RGS5 levels. | ||||||